JERUSALEM, May 30 /PRNewswire-FirstCall/ -- IDenta Corp. announced today that it is developing a new chemical detection product that is not oriented to detecting the presence of illicit drugs. The venture was prompted by recent discussions with legal and law enforcement experts from a number of countries, including the U.S. Department of Homeland Security, which unveiled a variety of potential new applications for the company's technical expertise and product packaging.
"This may well be a paradigm shift for IDenta, opening the opportunity to develop a totally new product line," announced IDenta CEO Yaacov Shoham. "When you simply identify what IDenta does, it becomes clear that there are numerous new products in addition to drug detection products, that we can develop and manufacture. IDenta is the business of identifying substances at the places where they are found. We have the technical background in chemistry to identify types of dangerous substances including our current line of drug detection products. We also have the product packaging knowledge which we can easily adapt to new detection products."
The product's use and name is expected to be revealed in 2-3 months after IDenta conducts product performance tests and develops formal procedures. "We believe that this new product will quickly be seen as the best in its field, just as our drug detection products have gained that distinction."
About IDenta
IDenta Corporation is one of the world's leading providers of proprietary on-site drug detection kits for governmental, professional and civilian use. Information concerning IDenta's product line, including rapid test kits (substance only) for the detection of marijuana, hashish, ketamine, ecstasy, cocaine, crack, heroin, amphetamines and methamphetamines may be found at http://www.IDenta.biz and http://www.drugsdetector.com
For Investor Relations, lobbying interests or information concerning IDenta's products internationally contact: Yaacov Shoham, IDenta Corp., CEO Tel: +972-52-6554487, +972-8-9716874 Fax: +972-8-9716875 fpi@drugsdetector.com For Investor Relations in the United States contact: Randy Jacobs, SITCOM LLC IDentaNews@sitcomllc.com +1-800-316-9437 Identa Corp. USA address: (new) 530 Stephenson Avenue Savannah, Georgia 31405 Tel: +1-912-652-4818
Certain of the statements contained herein may be, within the meaning of the federal securities laws, "forward-looking statements" that are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements are based on management's expectations as of the date hereof, and the company does not undertake any responsibility to update any of these statements in the future.
IDenta Corp.CONTACT: For Investor Relations, lobbying interests or informationconcerning IDenta's products internationally contact: Yaacov Shoham, IDentaCorp., CEO, Tel: +972-52-6554487, +972-8-9716874, Fax: +972-8-9716875,fpi@drugsdetector.com. For Investor Relations in the United States contact:Randy Jacobs, SITCOM LLC, IDentaNews@sitcomllc.com, +1-800-316-9437, IdentaCorp. USA address: (new), 530 Stephenson Avenue, Savannah, Georgia 31405,Tel: +1-912-652-4818
